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Abstract
This study investigated the overall clinical impact of anti-α-
actinin antibodies in patients with pre-selected autoimmune
diseases and in a random group of anti-nuclear antibody (ANA)-
positive individuals. The relation of anti-α-actinin antibodies with
lupus nephritis and anti-double-stranded DNA (anti-dsDNA)
antibodies represented a particular focus for the study. Using a
cross-sectional design, the presence of antibodies to α-actinin
was studied in selected groups, classified according to the
relevant American College of Rheumatology classification
criteria for systemic lupus erythematosus (SLE) (n  = 99),
rheumatoid arthritis (RA) (n = 68), Wegener's granulomatosis
(WG) (n = 85), and fibromyalgia (FM) (n = 29), and in a random
group of ANA-positive individuals (n = 142). Renal disease was
defined as (increased) proteinuria with haematuria or presence
of cellular casts. Sera from SLE, RA, and Sjøgren's syndrome
(SS) patients had significantly higher levels of anti-α-actinin
antibodies than the other patient groups. Using the geometric
mean (± 2 standard deviations) in FM patients as the upper
cutoff, 20% of SLE patients, 12% of RA patients, 4% of SS
patients, and none of the WG patients were positive for anti-α-
actinin antibodies. Within the SLE cohort, anti-α-actinin
antibody levels were higher in patients with renal flares (p =
0.02) and correlated independently with anti-dsDNA antibody
levels by enzyme-linked immunosorbent assay (p < 0.007) but
not with other disease features. In the random ANA group, 14
individuals had anti-α-actinin antibodies. Of these, 36% had
SLE, while 64% suffered from other, mostly autoimmune,
disorders. Antibodies binding to α-actinin were detected in 20%
of SLE patients but were not specific for SLE. They correlate
with anti-dsDNA antibody levels, implying in vitro cross-
reactivity of anti-dsDNA antibodies, which may explain the
observed association with renal disease in SLE.
Introduction
A wide spectrum of organ non-specific autoantibodies can be
detected in sera of patients with systemic lupus erythemato-
sus (SLE) [1]. Although the clinical significance of many of
these autoantibodies remains unclear, anti-double-stranded
DNA (anti-dsDNA) antibodies (Abs) are among the most SLE-
specific autoantibodies and are also involved in the pathogen-
esis of lupus nephritis (LN) [2-7]. Given the consequences of
LN in terms of morbidity, mortality, and treatment-related toxic-
ity, increased knowledge on the pathophysiology of LN is
needed to develop therapeutic interventions that are more
rational. Intraglomerular immune complex depositions are a
hallmark of LN, and anti-dsDNA Abs can be eluted from
affected kidneys in both human and experimental LN [8-10].
The glomerular target structures for anti-dsDNA Abs, however,
are still controversial, and to determine structures that de facto
bind Abs in vivo is more important than to determine potential
cross-reactions of nephritogenic autoantibodies.
Several models explain anti-dsDNA Ab binding in the glomer-
uli. In one model, Ab binds to externalised nucleosomes
present in basement membranes and the mesangium of
glomeruli [11,12], whereas other models focus on Ab binding
Ab = antibody; ANA = anti-nuclear antibody; anti-dsDNA = anti-double-stranded DNA; CRP = C-reactive protein; EliA = fluorescence enzyme immu-
noassay test for anti-double-stranded DNA (Phadia GmbH); ELISA = enzyme-linked immunosorbent assay; FM = fibromyalgia; LN = lupus nephritis; 
OD = optical density; RA = rheumatoid arthritis; Rs = Spearman's rho; SLE = systemic lupus erythematosus; SLEDAI = Systemic Lupus Erythema-
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to basement membrane constituents, either by specific recog-
nition or by cross-reaction of anti-dsDNA Abs [5,13]. Recent
reports have indicated that anti-dsDNA Abs may specifically
cross-react with intraglomerular, extracellular α-actinin in
patients with LN [14-19]. The rod-shaped α-actinin proteins
are central to the organisation of the cytoskeleton as they bind
and crosslink actin [20]. In the kidney, α-actinin has been
detected in mesangial cells, podocytes, capillaries, and larger
blood vessels [20-23], where it plays a role in the formation of
adhesion receptors [24-27] that link the cytoskeleton with the
extracellular matrix [28-31]. There is also evidence that mem-
brane-associated  α-actinin is accessible on the surface of
mesangial cells [15,18], and the increased glomerular α-
actinin expression after epithelial podocyte confluence and the
occurrence of proteinuria suggest a role for α-actinin in renal
pathophysiology [32,33]. In view of the above, it seems
improbable that the intraglomerular presence of (non-muscle)
α-actinin would be a specific occurrence in patients with LN,
although an Ab response to α-actinin may still be specific for
SLE and contribute to LN.
Therefore, the presence of α-actinin-binding Abs was investi-
gated in patients with various autoimmune systemic inflamma-
tory diseases, including SLE. Furthermore, because anti-
dsDNA Abs are thought to mediate their nephritogenic poten-
tial in patients with SLE through cross-reactive α-actinin bind-
ing, we analysed the associations between α-actinin binding
and clinical and immunological manifestations in patients with
SLE in more detail.
Materials and methods
Patients and definitions
Abs to α-actinin were analysed in a cross-sectional study in
two different sets of patients. First, patients were selected
based on scientific classification according to the relevant
American College of Rheumatology classification criteria for
SLE (n = 99), rheumatoid arthritis (RA) (n = 68), Wegener's
granulomatosis (WG) (n = 85), and fibromyalgia (FM) (n = 29)
[34-37]. Patients included in disease registries, which are
approved by the Regional Ethics Committee, gave informed
written consent. In addition, Abs to α-actinin were analysed in
142 consecutively collected anti-nuclear Ab (ANA)-positive
sera, in which subsequent clinical diagnoses were settled
without the knowledge of the serological analyses [38].
Detailed information on these cohorts has been published
before [38-41], and demographic data for the different sub-
groups are given in Table 1. Disease activity in patients with
SLE was determined by the calculation of a Systemic Lupus
Erythematosus Disease activity index (SLEDAI), based upon
clinical findings in the 2 weeks prior to sample collection.
Renal flares were defined according to the SLEDAI definition
of new onset or recent increase (>0.5 g per 24 hours) of pro-
teinuria. In eight patients, renal biopsy verified the LN diagno-
sis, whereas three patients were treated for a relapse of earlier
(1 to 3 years) biopsy-confirmed LN. In these three patients, LN
diagnosis was not confirmed by biopsy and was based solely
on the SLEDAI definition.
ANA screening assay
ANAs were determined by a screening enzyme-linked immu-
nosorbent assay (ELISA) (Phadia GmbH, Freiburg, Germany,
formerly Pharmacia Diagnostics), using the assay protocol
recommended by the manufacturer. Cutoff was controlled as
described previously [42] and verified the cutoff suggested by
the manufacturer.
Anti-DNA Ab assays
Abs to dsDNA by ELISA were determined and quantified by a
widely used commercially available and internationally vali-
dated anti-DNA Ab kit (Varelisa; Phadia GmbH). The cutoff val-
ues were determined locally through a continuously running
internal quality assessment program, as recently described
[42]. Lot-to-lot variation of analytical ELISA-based kits, rele-
vant to the determination of cutoff values, was examined and
adjusted when necessary by internal and external reference
Abs. The selected cutoff value agreed with other laboratories
participating in national and international quality assessment
programs. A result was regarded as positive at greater than or
equal to 55 Units for the anti-dsDNA ELISA. This cutoff value
is regarded as sufficient to avoid Abs we regard as insignifi-
cant and epiphenomenological from insight into their origin
and clinical impact and are in line with cutoff values adapted
by other laboratories [43].
Table 1
Demographics and α-actinin binding in the various disease groups
Disease group Female/male ratio 
(percentage)
Age in years (range) OD α-actinin binding 
(range)
No. (percentage) with 
positive α-actinin binding
RA (n = 68) 65/35 67.7 (24 to 85) 0.102 (0.06 to 0.26)a 8 (12)a
SLE (n = 99) 92/8 35.7 (15 to 73) 0.112 (0.05 to 0.63)a 20 (20)a
WG (n = 85) 57/43 49.1 (17 to 76) 0.053 (0.04 to 0.08) 0 (0)
ANA-positive (n = 142) 63/37 52.2 (6 to 78) 0.09 (0.06 to 0.90) 46 (32)a
aIndicates significant difference compared with WG category. Numbers represent mean values (range) unless otherwise indicated. ANA, anti-
nuclear antibody; OD, optical density; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; WG, Wegener's granulomatosis.Available online http://arthritis-research.com/content/8/6/R162
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The fluorescence enzyme immunoassay for anti-dsDNA by
EliA test (Phadia GmbH) was processed using UniCap100
(Phadia GmbH) as recommended by the manufacturer [44].
Bound human anti-dsDNA Abs were detected by mouse anti-
human Fcγ Ab conjugated with β-galactosidase and 4-methy-
lumbelliferyl-β-D-galactoside as substrate. Washing of the
wells was performed using a stringent washing buffer, which
dissociates and thereby avoids detection of low-avidity Abs. A
six-point standard curve calibrated against World Health
Organization reference sera was used for quantitative meas-
urements, and results are given as arbitrary IU, with a positive
result defined as greater than or equal to 20 IU.
Anti-α-actinin assay
Abs to α-actinin were determined by an in-house ELISA test
using chicken α-actinin (Sigma-Aldrich, St. Louis, MO, USA)
as target antigen, as described recently [45]. All sera were
titrated by twofold dilution. Because the values in general were
very low, data are presented as optical density (OD)490 nm at
1:100 dilution. Goat polyclonal immunoglobulin G anti-α-
actinin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA)
was used as an intra-assay positive control Ab. A result was
defined as positive if the mean OD was higher than the geo-
metric mean (± 2 standard deviations) level of binding of FM
sera to α-actinin resulting in a cutoff level of OD 0.133 at 490
nm, if not otherwise stated in the text.
Statistics
Differences between values for the various groups were ana-
lysed with Fisher exact test for dichotomous variables and
Kruskal-Wallis test for continuous variables, and correlations
were estimated by Spearman rank test coefficient. Nonpara-
metric tests were chosen because of the skewness of the
data. To determine the independence of factors with a signifi-
cant Spearman rank correlation to α-actinin binding, multivari-
ate regression analyses were performed in a step-up method
(p < 0.1 to enter). All analyses were performed using SPSS
version 11.0 (SPSS Inc., Chicago, IL, USA). Resulting two-
sided  p  values < 0.05 were considered to indicate
significance.
Results
Diagnostic impact of anti α-actinin Abs in pre-selected 
groups or in ANA-positive individuals
The frequency of anti-α-actinin Abs in the pre-selected groups
was 5.9% when combining RA and WG patients in one group,
whereas the frequency was 20% in the SLE group (Table 1).
Although the fourfold-higher frequency in SLE was statistically
significant, analysing pre-selected groups of patients might
have introduced bias by excluding a wider array of conditions
in which Abs to α-actinin potentially may be produced. To test
for this, another approach was undertaken with patients
selected purely on the basis of a positive ANA test. Because
ANA may be present in a wide variety of conditions and also
among normal individuals, the bias toward SLE for this
approach is insignificant [46].
In the ANA-positive group, 46 (32%) individuals were positive
for Abs to α-actinin at the cutoff value of OD490 nm at 0.133.
These patients demonstrated a large spectrum of disorders,
and anti-dsDNA Abs were most frequently but not exclusively
found in patients with SLE (Table 2). Notwithstanding this
wide disease spectrum, there was a significant correlation
between anti-dsDNA Ab and anti-α-actinin Ab levels present
in this ANA-positive cohort (Spearman's rho [Rs] 0.27, p =
0.04). Using a more restricted cutoff value (OD490 nm of 0.2
after subtraction of background binding in albumin-coated
wells), 14 patients remained positive and these patients were
later diagnosed with the following: SLE (n = 5), Sjøgren's syn-
drome (SS) (n = 3), discoid lupus erythematosus (n = 1), RA
(n  = 1), arthralgia (n  = 1), urinary tract infection (n  = 1),
autoimmune hepatitis (n = 1), and unclassified connective tis-
Table 2
Results of anti-dsDNA testing according to disease classification in ANA-positive subjects
Anti-dsDNA (ELISA) Anti-dsDNA (EliA)
Disease classification Percentage positive Titre (IU) (SD) Percentage positive Titre (IU) (SD)
SLE (n = 39) 79 171 (51) 44 138 (196)
SS (n = 22) 18 152 (70) 12 89 (56)
RA (n = 17) 29 200 (0) 6 48 (2)
UCTD (n = 9) 22 194 (8) 22 59 (0.2)
Various (n = 57)a 35 143 (82) 22 36 (49)
Values represent mean values (SD) unless otherwise indicated. aIncludes patients with viral hepatitis, angina pectoris, apnoea syndrome, 
arthralgia/lumbago, asthma/bronchitis, cataract/cornea bleeding, claudicatio intermittens, cerebrovascular accident, epilepsy, erythematosus 
nodosum, fibromyalgia, haematuria, headache, hypothyroidism, urinary tract infections, solid cancer, menisc rupture, migraine, myasthenia gravis, 
panniculitis, psoriasis, rash, urine incontinence, observation, periorbital edema, and Stevens-Johnson syndrome. Anti-dsDNA, anti-double-
stranded DNA; EliA, fluorescence enzyme immunoassay test for anti-double-stranded DNA (Phadia GmbH); ELISA, enzyme-linked 
immunosorbent assay; RA, rheumatoid arthritis; SD, standard deviation; SLE, systemic lupus erythematosus; SS, Sjøgren's syndrome; UCTD, 
unclassified connective tissue disease.Arthritis Research & Therapy    Vol 8 No 6    Becker-Merok et al.
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sue disease (n  = 1). This confirms that anti-α-actinin Abs
occur among random, ANA-positive, non-SLE patients [45].
There were significant differences in the levels of anti-α-actinin
Abs in the selected disease groups (Table 1). Patients with
SLE and RA had higher OD values than patients with WG and
also compared with the randomised ANA-positive patients (p
= 0.01). The differences between the SLE and RA groups
were not significant as was the case also between WG and
ANA-positive patients (all p values > 0.3). In a sub-analysis of
ANA-positive patients, anti-α-actinin Ab levels were also
higher in those with SLE, RA, and SS compared with patients
with other disorders (p = 0.05, data not shown), although dif-
ferences between SLE, RA, and SS patients were not
significant.
Correlation between α-actinin binding and disease 
features in SLE cohort
Levels of anti-dsDNA Abs in both the ELISA and the EliA assay
as well as clinical disease activity (SLEDAI) scores were sig-
nificantly correlated with the presence of anti-α-actinin Abs
(Table 3, Figure 1). This remained unaltered after Bonferroni
correction and also when excluding the three outliers (Rs 0.35,
p = 0.001). In addition, C-reactive protein (CRP) levels, eryth-
rocyte sedimentation rate, damage index (p < 0.05), and age
(p = 0.051) correlated with anti-α-actinin Abs prior to Bonfer-
roni correction, whereas no correlation was seen with quanti-
tative renal features such as proteinuria or serum creatinin
levels (Table 3). In a multivariate regression analysis, only anti-
dsDNA Abs detected by ELISA remained independently cor-
related with α-actinin binding (Table 4).
Correlation between anti-α-actinin Abs and renal flares 
in SLE cohort
Renal disease flares, as defined in Materials and methods,
were present in 14 patients in the pre-selected SLE group.
These patients had higher levels of anti-α-actinin Ab binding
(median OD490 nm 180 versus 100, p = 0.002) (Figure 2) as
well as higher SLEDAI scores (9 versus 2, p = 0.001) and anti-
dsDNA Ab levels by EliA (67.9 versus 12.1 (median), p =
0.013) than patients without renal flare, and both CRP and
dsDNA Ab levels by ELISA did not differ (p values > 0.2; data
not shown). Using the standard cutoff value (OD490 nm 0.133),
43% of patients with LN were positive for α-actinin Abs versus
17% of SLE patients without nephritis (p = 0.034; odds ratio
3.8, confidence interval 1.1 to 12.7), and 71% of patients with
LN tested positive for anti-dsDNA Abs (EliA) versus 45% of
SLE patients without nephritis (p = 0.08). The proportion of
patients with positive ELISA anti-dsDNA Ab findings did not
differ between both groups (71% versus 49%, p = 0.156).
Discussion
In the present study, a critical analysis of the clinical impact of
Abs to α-actinin was performed, with a focus on their diagnos-
tic significance and alleged correlation with LN. To obtain
sound information, two principally different analytical models
were tested; in one model, pre-selected groups of patients
with established diagnosis were analysed, whereas the other
implemented a randomised group of patients in which a posi-
tive ANA test was the only selection criterion. The wider scope
of this two-sided approach increases the reliability of data on
the value of diagnostic testing in general and puts the clinical
significance of Abs to α-actinin in a broader perspective than
prior studies.
Table 3
Correlation between α-actinin-binding antibody levels and clinical findings in patients with SLE
Disease feature Spearman's rho p value
Anti-dsDNA Ab ELISA (IU/ml) 0.638 0.0001a
Anti-dsDNA Ab EliA (IU/ml) 0.601 0.0001a
Total SLEDAI score 0.378 0.0001a
ESR 0.254 0.035
CRP (mg/l) 0.236 0.048
C3 (mg/l) -0.102 0.522
C4 (mg/l) -0.078 0.623
Age (years) -0.197 0.051
Creatinin clearance (ml/minute) 0.339 0.199
Proteinuria (g/24 hours) 0.182 0.484
Renal SLICC score -0.031 0.796
Total SLICC -0.385 0.0053
aSignificant results (p < 0.005) after the Bonferroni correction. C3, complement factor 3; C4, complement factor 4; CRP, C-reactive protein; EliA, fluorescence enzyme 
immunoassay test for anti-double-stranded DNA (Phadia GmbH); ELISA, enzyme-linked immunosorbent assay; ESR, erythrocyte sedimentation rate; SLE, systemic 
lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease activity index; SLICC, Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology Damage Index for systemic lupus erythematosus.Available online http://arthritis-research.com/content/8/6/R162
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Table 4
Multivariate models building on all significant factors in univariate analysis
Model Feature Unstandardised coefficients (B) Standard error Standardised coefficients beta tp   value
1 (Constant) 74.907 23.552 3.180 0.003
Anti-dsDNA (ELISA) Ab (U/ml) 0.413 0.149 0.381 2.765 0.008
2 (Constant) 72.028 23.730 3.035 0.004
Anti-dsDNA (ELISA) Ab (U/ml) 0.520 0.184 0.480 2.828 0.007
Anti-dsDNA Ab – EliA (IU/ml) -0.142 0.142 -0.169 -0.997 0.324
3 (Constant) 68.464 26.533 2.580 0.013
Anti-dsDNA (ELISA) Ab (U/ml) 0.512 0.187 0.472 2.732 0.009
Anti-dsDNA Ab – EliA (IU/ml) -0.137 0.145 -0.163 -0.947 0.349
Total SLEDAI score 1.153 3.676 0.044 0.314 0.755
4 (Constant) 63.596 31.159 2.041 0.048
Anti-dsDNA (ELISA) Ab (U/ml) 0.506 0.190 0.467 2.658 0.011
Anti-dsDNA Ab – EliA (IU/ml) -0.132 0.147 -0.158 -0.901 0.373
Total SLEDAI score 1.013 3.743 0.039 0.271 0.788
ESR (mm) 0.208 0.677 0.044 0.307 0.761
5 (Constant) 65.107 31.917 2.040 0.048
Anti-dsDNA (ELISA) Ab (U/ml) 0.512 0.194 0.473 2.646 0.012
Anti-dsDNA Ab – EliA (IU/ml) -0.133 0.149 -0.159 -0.897 0.375
Total SLEDAI score 1.137 3.808 0.044 0.299 0.767
ESR (mm) 2.558 × 10-03 0.922 0.005 0.028 0.978
CRP (mg/l) 0.154 0.522 0.057 0.295 0.769
6 (Constant) 61.031 58.443 1.044 0.303
Anti-dsDNA (ELISA) Ab (U/ml) 0.513 0.196 0.473 2.614 0.013
Anti-dsDNA Ab – EliA (IU/ml) -0.128 0.164 -0.152 -0.780 0.440
Total SLEDAI score 1.196 3.919 0.046 0.305 0.762
ESR (mm) 8.484 × 10-03 0.956 0.002 0.009 0.993
CRP (mg/l) 0.144 0.541 0.053 0.267 0.791
Age 0.108 1.284 0.015 0.084 0.934
7 (Constant) 59.716 59.051 1.011 0.318
Anti-dsDNA (ELISA) Ab (U/ml) 0.542 0.206 0.501 2.627 0.012
Anti-DNA-EliA (IU/ml) -0.134 0.166 -0.160 -0.808 0.424
Total SLEDAI score 1.772 4.116 0.068 0.430 0.669
ESR (mm) -6.240 × 10-03 0.965 -0.001 -0.006 0.995
CRP (mg/l) 0.144 0.546 0.053 0.264 0.794
Age -0.193 1.425 -0.028 -0.135 0.893
Total SLICC 5.964 11.773 0.095 0.507 0.615
Ab, antibody; anti-dsDNA, anti-double-stranded DNA; CRP, C-reactive protein; EliA, fluorescence enzyme immunoassay test for anti-double-
stranded DNA (Phadia GmbH); ELISA, enzyme-linked immunosorbent assay; ESR, erythrocyte sedimentation rate; SLEDAI, Systemic Lupus 
Erythematosus Disease activity index; SLICC, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage 
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In this study, Ab binding of α-actinin was four to five times
more prevalent in SLE than in the other pre-selected diagnos-
tic groups. This could indicate that Abs to α-actinin might
serve as a diagnostically valuable parameter for SLE. How-
ever, in a randomised ANA-positive group, the anti-α-actinin
Ab was more prevalent in non-SLE patients than in SLE
patients. The 20% prevalence of these Abs in SLE patients
together with its low specificity compared with other rheuma-
tologic and noninflammatory diseases indicate that testing for
this Ab is not likely to be useful in diagnosing systemic autoim-
mune disease states. The data demonstrate that the diagnos-
tic power of a given parameter – here, the anti-α-actinin Ab –
should ideally be determined in randomised studies and not
(only) in selected groups of patients. This is in agreement with
results from studies of the diagnostic impact of different ana-
lytical methods for anti-dsDNA Abs in the same ANA-positive
group of individuals [38].
Within the SLE cohort, α-actinin Abs correlated with features
of disease activity, including anti-dsDNA Ab levels. Specifi-
cally, renal involvement was associated with higher α-actinin
Ab binding, and α-actinin-positive lupus patients were 3.8
times more likely to have renal involvement. Thus, in patients
with established SLE, α-actinin Abs may be associated in
some way with renal disease.
A specific role for α-actinin-binding Abs in the pathophysiol-
ogy of (renal) disease in SLE has not yet been defined. The
fact that anti-dsDNA Ab presence was the sole independent
factor for α-actinin Ab presence in this multivariate analysis,
however, provides indirect support for earlier observations of
cross-reactions between anti-dsDNA Abs and α-actinin. The
demonstration of Abs to α-actinin in eluates from nephritic
murine kidneys indicates that this Ab population is present in
nephritic glomeruli. However, just as serological profiles of
Figure 1
Scatterplots representing the relationship between α-actinin antibody  (Ab) binding and levels of anti-double-stranded DNA (anti-dsDNA) Abs  in the pre-selected diagnostic groups Scatterplots representing the relationship between α-actinin antibody 
(Ab) binding and levels of anti-double-stranded DNA (anti-dsDNA) Abs 
in the pre-selected diagnostic groups. The relationship of α-actinin Ab 
binding with anti-dsDNA Abs detected by enzyme-linked immunosorb-
ent assay (ELISA) (a) or by EliA assay (b) and with overall disease 
activity (SLEDAI) (c). Broken lines indicate cutoff levels for the respec-
tive assays (see Materials and methods for analytical details). EliA, fluo-
rescence enzyme immunoassay test for anti-dsDNA (Phadia GmbH); 
OD, optical density; Rs, Spearman's rho; SLEDAI, Systemic Lupus Ery-
thematosus Disease activity index.
Figure 2
Box plot of the optical density (OD) of α-actinin binding in patients from  pre-selected systemic lupus erythematosus group with and without  renal flares Box plot of the optical density (OD) of α-actinin binding in patients from 
pre-selected systemic lupus erythematosus group with and without 
renal flares. Thick bars indicate median values, and boxes border the 
interquartile range. Asterisks represent outliers.Available online http://arthritis-research.com/content/8/6/R162
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anti-dsDNA Abs do not necessarily predict the development of
LN, this also holds true for α-actinin-binding Abs because nei-
ther DNA nor α-actinin is normally an available target antigen
in the kidney. By analogy with glomerular binding of anti-
dsDNA Abs requiring nucleosomes to become accessible in
the extra-cellular space, intra-glomerular anti-α-actinin Ab dep-
osition would require the release of α-actinin in extra-cellular
space. Recent results from our laboratory demonstrate the
presence of extra-cellular, intraglomerular α-actinin in
nephritic, but not in healthy, murine glomeruli [45]. Also, even
though subgroups of anti-dsDNA Abs may cross-react with α-
actinin in vitro, this does not support the conclusion that this
protein also represents the intra-glomerular target for anti-
dsDNA Abs in LN. Thus, the present data do not prove a
causal relationship between Abs to α-actinin and nephritis.
Indirect in vitro evidence from experimental LN indicates a
possible role for cross-reactive binding of anti-dsDNA Abs to
intraglomerular antigens in the absence of DNA [15,18], but
definite in vivo proof is lacking. In contrast, the distribution of
glomerular α-actinin did not correlate with the distribution of in
vivo-bound, glomerular basement membrane-associated
autoantibodies in a recent study [45]. These findings suggest
that anti-α-actinin Abs mainly constitute an epiphenomena
with limited clinical relevance. Confirming a role in monitoring
patients with established SLE for renal disease would require
proof from longitudinal studies.
Some limitations apply to the findings presented here. Overall,
the mean level of Ab binding to α-actinin (by OD) in the dis-
ease subgroups was quite low. Both mean levels and cutoff
levels reported here are, however, in agreement with other
findings on anti α-actinin Ab binding in humans [45,47,48].
Nonetheless, it may be argued that such low OD values are
not meaningful, especially as the potential pathophysiological
significance of the presence of α-actinin Abs remains unclear.
Patients in the ANA-positive cohort were classified according
to established guidelines; however, our approach to exclude
anti-dsDNA Ab as a criterion may have introduced a bias
toward non-SLE cohorts. Also, the prevalence and disease
severity of LN and autoantibodies are markedly higher in non-
white populations. The exclusive Caucasian make-up of these
cohorts makes it difficult to extrapolate our findings to cohorts
of different ethnic background. Although our cutoff levels for
normal values were based on FM patients, who do not have an
inflammatory autoimmune disorder and in whom levels were
comparable with those in healthy controls, this nonetheless
may have introduced bias in our results.
Conclusion
The impact of Abs to α-actinin as diagnostic markers for SLE
is limited. The association between renal involvement in SLE
and the presence of Abs to α-actinin is likely the result of
cross-reactive anti-dsDNA Abs. A pathophysiological role for
cross-reactivity of anti-dsDNA Abs with extracellular α-actinin
in vivo, however, is not supported by experimental models for
LN.
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